Anticancer Fund’s Post

This weekend, the American Society of Clinical Oncology (ASCO) conference showcased ground-breaking advancements in the treatment of leukaemia and other haematological malignancies as well as a host of other cancers. A pivotal Phase 3 trial (the ASC4FIRST study) was presented, comparing the first in class drug asciminib with other tyrosine kinase inhibitors (TKIs) in newly diagnosed chronic myeloid leukaemia (CML) patients. The promising results provide evidence that asciminib could become potentially become a first-line treatment in CML, although longer- term follow up data will be needed first. Currently asciminib is available to certain CML patients if other two or more other TKIs have been tried first. Additionally, significant progress was showcased at ASCO in hematopoietic stem cell transplants. A Phase 1 study of STC-15, a METTL-3 inhibitor, showed encouraging results in patients with advanced malignancies, demonstrating safety and clinical activity. This lays the groundwork for Phase 2 trials later this year. Leukaemia UK has funded Dr Kostas Tzelepis's laboratory research at Cambridge on targeting METTL-3 in leukaemia in collaboration with STORM Therapeutics, which led this new trial. We are proud to support such pioneering laboratory work, which could help to underpin the development of potential new leukaemia treatments. https://lnkd.in/eQ3n8GnS #ASCO2024 #LeukemiaResearch #Oncology #Hematology #CancerTreatment #ClinicalTrials #InnovationInHealthcare

The American Society of Clinical Oncology (ASCO) Annual Meeting is an important event in the oncology field, bringing together top researchers, trialists and clinicians to discuss groundbreaking cancer research and innovative therapies. Held from May 31 to June 4, 2024, in Chicago, this year’s meeting continues to highlight significant advancements, with respect to newer therapies and newer approaches in cancer care. Whether it was newer therapies, the use of previously unused combinations or investigative approaches like ctDNA, it had’em all. However, it’s crucial to make such influential events more accessible to professionals from low to middle-income countries (LMICs). Providing scholarships, virtual attendance options, and enhanced partnerships can bridge the gap, ensuring broader participation and fostering global collaboration in the fight against cancer. By expanding opportunities for all, we can drive forward the mission of health for all. #ASCO2024 #Oncology #CancerResearch #GlobalHealth

This month we celebrate the 1-year anniversary of the #NationalCancerPlan, a framework for collaboration guiding our nation’s efforts against cancer. Our Panel Chair, Dr. Elizabeth Jaffee, is live at #AACR24 discussing how our 5 priority areas outlined in the #NationalCancerPlan report underscore opportunities to accelerate progress in cancer care, research, & training. Learn more about our first assessment of the #NationalCancerPlan: https://bit.ly/3SXRB0D 

𝗕𝗲𝗶𝗻𝗴 𝗽𝗿𝗼𝗮𝗰𝘁𝗶𝘃𝗲 We have created this special section on hereditary ovarian cancer filled with expert knowledge in order to empower women and their families, and help them take informed actions. In the following, you will find additional suggestions for further reading, listening, watching and thought. Learn more here: https://lnkd.in/egk6f3wz #ovariancancer #awareness #Eierstockkrebs

Immunotherapy, precision medicine, biomarkers, and pharmacist engagement...oh my! Signficant science and practice focus on delivering value and improving outcomes. Come join us for these conversations and more! Hit me up if you have questions. #oncology #IVBM #AJMC #evidencebasedmedicine #Boston #valuebasedcare

The 2023-2027 Virginia Cancer Plan (VCP) provides a roadmap to help Virginia residents address the burden of cancer. The plan provides data, guidance, information, and links to resources for all Virginians. See the plan and learn how you can help us achieve our goals: https://ow.ly/ByS350QLMVp #VirginiaCancerPlan

FORCE's XRAY reviews are short, plain language summaries of current issues about hereditary cancer. These include audience relevance, national guidelines, questions enrolling clinical trials and resources. Read more at: https://ow.ly/u6Ay50QL0FU #FacingOurRisk #HereditaryCancer

Early Detection by personal responsibility. It is the best if not only way for most of us all.

To the amazing employers out there – you can offer invaluable support to your employees on their #cancer journeys. Cancer Expert Now connects cancer patients with physicians and experts in the field so they can get critical information and advice when they need it. Visit https://ow.ly/FAwC50R7ylG to learn more about how you can support your employees through their cancer struggles. #CancerExpertNow #CancerExperts #CancerTreatment

In the world of #cancerresearch and #cancertreatment, the Dana-Farber Cancer Institute is synonymous with #innovation, #healthcareexcellence on every conceivable measure, and a beacon of hope for #cancerpatients. How it responds in the coming days, weeks, and months to this "issue" will be instructive and is being watched by the medical-scientific-research community around the world. We need them to succeed! #researchmatters #sciencematters #integritymatters https://lnkd.in/etjNdAiq